Business Wire

HPCAIAC

Share
HPC-AI Advisory Council and National Supercomputing Centre Singapore Expand 3rd APAC HPC-AI Competition to Address COVID-19

The HPC-AI Advisory Council (HPCAIAC) and the National Supercomputing Centre (NSCC) Singapore announced today that they have joined the global fight against COVID-19 by expanding the 2020 APAC HPC-AI competition to address education and applied learning towards accelerating bioscience research and discovery.

As part of the updated competition, student teams are now tasked to research, find and choose an HPC or AI application that can potentially be used as part of the global fight against COVID-19. Teams must demonstrate testing and benchmarking of the application, as well as explain how this application can best be accelerated. In addition, teams will also be required to focus on tuning and accelerating NAMD, a molecular dynamics code designed for high-performance simulation of large biomolecular systems. The NAMD application is being used at various supercomputing sites to run massive simulations of COVID-19 to aid researchers design new drugs and vaccines to combat the virus.

The APAC HPC-AI competition promotes the latest HPC and AI technologies to the universities and research centers and trains the students with the latest HPC and AI technologies to help bridge the gap between universities/research institutes and industries. The competition also trains the undergraduate and graduate students to practice on the newest HPC and AI platforms, and provides the key ingredients and industry tools to optimize the production applications. Open for registration until May 17, the 3rd Annual 2020 APAC HPC-AI competition expects to host multiple teams from across the APAC region.

“While not ignoring commercial and scientific applications, it has become importantly clear that we must put further emphasis on tuning and optimizing applications in the medical and bioscience field. By expanding the competition’s charter to address applications specifically used for groundbreaking COVID-19 simulations, the HPC-AI Advisory Council and NSCC are taking the action to educate and train the next generation of HPC scientists and programmers that may aid the world in viral outbreaks or pandemics in the future,” said Gilad Shainer, Chairman of the HPC-AI Advisory Council.

"Computer models of viruses and viral protein structures, especially for high resolution analysis, is very computationally intensive. Molecular docking experiments in silico, to screen for potentially effective drugs that block viral functions, and molecular-modeling applications, such as GROMACS and NAMD, must be optimized and benchmarked for simulations to run as efficiently as possible. By training our young aspiring programmers using real-world scenarios such as COVID-19, we can better prepare them to provide solutions to future global issues from pandemics to climate change. More than that, we hope that this will give our youth a better appreciation for the significant role that HPC and AI can play, and how they can use the skills learned in this competition to contribute more meaningfully to society," said Professor Tan Tin Wee, Chief Executive, National Supercomputing Centre (NSCC) Singapore.

Co-organized by the HPC-AI Advisory Council and NSCC, the competition is sponsored by Mellanox, NVIDIA, AMD and WekaIO with additional support from the Singapore Advanced Research and Education Network (SingAREN).

For more information on the 3rd APAC HPC-AI competition and to register teams, please visit the HPC-AI Advisory Council website at http://hpcadvisorycouncil.com/events/2020/APAC-AI-HPC/

About HPC-AI Advisory Council

Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to bridge the gap between high-performance computing and artificial intelligence use and its potential, bringing the beneficial capabilities of HPC and AI to new users for better research, education, innovation and product manufacturing, and brings users the expertise needed to operate HPC and AI systems, provide application designers with the tools needed to enable parallel computing, and to strengthen the qualification and integration of HPC and AI system products. For more information, please visit: www.hpcadvisorycouncil.com .

About National Supercomputing Centre Singapore

The National Supercomputing Centre (NSCC) Singapore was established in 2015 and manages Singapore’s first national petascale facility with available high performance computing (HPC) resources. As a National Research Infrastructure we support the HPC research needs of the public and private sectors, including research institutes, institutes of higher learning, government agencies and companies. With the support of its stakeholders, including Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), National University of Singapore (NUS), Singapore University of Technology and Design (SUTD), National Environment Agency (NEA) and Technology Centre for Offshore and Marine, Singapore (TCOMS), and funded by the National Research Foundation (NRF), NSCC catalyses national research and development initiatives, attracts industrial research collaborations and enhances Singapore’s research capabilities. For more information, please visit https://www.nscc.sg/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye